阿托瓦斯塔丁通过LRp5受体通路抑制大动脉膜中高胆固醇血清症诱导的化
Nalini M Rajamannan1, Malayannan Subramaniam, Frank Caira
1Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. n-rajamannan@northwestern.edu
Circulation
|September 15, 2005
概括
阿托瓦斯塔丁通过抑制Lrp5/β-catenin通路来降低高胆固醇血症中的大动脉结石化. 这一途径对于细胞增殖和骨形成在膜心脏病中至关重要.
科学领域:
- 心血管生物学 心血管生物学
- 分子医学是分子医学.
- 生物矿物化 生物矿物化
背景情况:
- 动脉疾病是门置换的主要原因之一.
- 导致门化的细胞机制尚不清楚.
- 低密度受体相关蛋白5 (Lrp5) 通过β-catenin信号传递对细胞增殖和骨质母细胞生成至关重要.
研究的目的:
- 在实验性高胆固醇血症期间研究LRp5在主动脉 (AV) 化中的作用.
- 为了确定阿托瓦斯塔丁对AV化和相关分子通路的影响.
主要方法:
- 瓦塔纳贝子被养正常的,富含胆固醇的或富含胆固醇的阿托瓦斯塔丁食.
- 对大动脉进行了细胞增殖,LRp5/β-catenin信号传递和骨基质标记物的分析.
- 在体外研究中,研究了阿托瓦斯塔丁对AV肌纤维细胞增殖和LRp5/β-catenin通路的影响.
主要成果:
- 胆固醇饮食诱导了AV化,增加了LRp5,骨质和p42/44的表达.
- 阿托瓦斯塔丁治疗显著降低了AV骨形成,细胞增殖和LRp5/β-catenin水平.
- 实验室发现证实了LRp5/β-catenin参与肌纤维细胞增殖.
结论:
- 高胆固醇血的AV化被阿托瓦斯塔丁减弱.
- 在这个过程中,Lrp5/β-catenin通路是关键的调解者.
- 准这种途径可能为膜心脏病提供治疗策略.
相关概念视频
Antihypertensive Drugs: Action of Calcium Channel Blockers
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Cholesterol: Significance and Regulation
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


